Shenyang Xingqi Pharmaceutical Co.,Ltd. Share Price

Equities

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 12/06/2024 BST 5-day change 1st Jan Change
194.7 CNY +0.78% Intraday chart for Shenyang Xingqi Pharmaceutical Co.,Ltd. +1.79% +49.51%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 2.12B 292M 22.97B Sales 2025 * 2.68B 369M 29.08B Capitalization 33.96B 4.68B 368B
Net income 2024 * 449M 61.89M 4.87B Net income 2025 * 669M 92.22M 7.26B EV / Sales 2024 * 16 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
75.7 x
P/E ratio 2025 *
50.8 x
Employees 1,995
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.96%
More Fundamentals * Assessed data
Dynamic Chart
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024 CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3% MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+0.78%
1 week+1.79%
Current month-5.48%
1 month-6.33%
3 months+38.81%
6 months+51.02%
Current year+49.51%
More quotes
1 week
185.29
Extreme 185.29
200.00
1 month
180.00
Extreme 180
214.36
Current year
92.86
Extreme 92.8571
214.36
1 year
80.17
Extreme 80.1684
214.36
3 years
40.05
Extreme 40.051
214.36
5 years
23.76
Extreme 23.7551
214.36
10 years
3.16
Extreme 3.1582
214.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 04/07/00
37 -
Director of Finance/CFO 50 31/12/02
Members of the board TitleAgeSince
Director/Board Member 51 01-04
Chairman 67 04/07/00
Chief Executive Officer 50 04/07/00
More insiders
Date Price Change Volume
13/06/24 194.7 +0.78% 3,873,032
12/06/24 193.2 -0.50% 2,079,523
11/06/24 194.2 +3.99% 2,629,849
07/06/24 186.7 -2.38% 2,810,530
06/06/24 191.3 +1.18% 3,096,913

End-of-day quote Shenzhen S.E., June 12, 2024

More quotes
SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Company’s main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
194.7
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300573 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW